Prognostic Stage IV Breast Cancer AJCC v8
56
9
18
19
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
13 trials with published results (23%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
8.9%
5 terminated out of 56 trials
79.2%
-7.4% vs benchmark
0%
0 trials in Phase 3/4
68%
13 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 19 completed trials
Clinical Trials (56)
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases